The in vitro treatment with Dac significantly reduced RABGEF1 expression, 24-OHC production, and TGF-β1 levels in control CRC cells but not in ATP6V0A1-deficient CRC cells (Fig. 10A–D). The gene discussed is ATP6V0A1; the disease is colorectal carcinoma.